HIGHBuilt-in & outside partyPipeline
Deramiocel
“10-K Item 1: 'Deramiocel is Capricor's lead product candidate and is being developed for the treatment of DMD'”
CAPR · Concentration risk · 10-K extracted
Capricor Therapeutics (CAPR) concentration risks
Updated
The most significant concentration Capricor Therapeutics discloses is Deramiocel, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Capricor Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH3
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
donor hearts
“10-K Item 1A: 'the manufacturing of our product candidates is dependent on complex supply chains, including the availability of donor hearts and other raw materials that are critical'”
HIGHOutside partyCounterparty
Nippon Shinyaku
“10-K Item 1A: 'we will depend on the ability of Nippon Shinyaku to perform according to the terms of the U.S. Distribution and Japan Distribution Agreements'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is that of an early-stage, single-asset therapeutic developer with compounding dependencies at the pipeline, supply-chain, and distribution levels. The lead product candidate, deramiocel, is the organizing priority for the entire enterprise — a high-share pipeline concentration where the character is mixed: it is structural in the sense that the company was formed around this program, but it also reflects dependency on a single asset whose regulatory and clinical trajectory determines virtually all of the company's near-term value. Reinforcing the pipeline concentration is a supply-chain dependency: the manufacturing process for the product candidates depends on complex supply chains, including the availability of donor hearts and other critical raw materials. This is a high-share dependency where the underlying input — donor hearts — is inherently supply-constrained and cannot be manufactured or stockpiled in the way conventional pharmaceutical raw materials can. A deterioration in donor heart availability would impair manufacturing capacity regardless of clinical or regulatory progress. Layered on top of both is a commercial distribution dependency: the company depends on Nippon Shinyaku to perform according to the terms of the U.S. Distribution and Japan Distribution Agreements, a high-share counterparty exposure covering key distribution markets. Together, these three disclosures describe a risk profile where a single therapy's development success must flow through a constrained raw-material supply chain and ultimately reach patients via a single named distribution partner. All three risks are linked — the failure of any one would limit the value realized from the other two, making the profile more compounding than additive.
For the engine’s reasoning on CAPR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| CAPR● | Capricor Therapeutics, Inc. | 3 | 0 | 0 | 3 |
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.